Clin2
NCT07537387Possibly a fitNot yet recruiting

Pegylated Interferon for Hepatitis B After Prior Treatment

Chronic Hepatitis b

Part of Digestive system, Infections clinical trials.

This study tests whether a long-acting interferon medication can help people with chronic hepatitis B who have already received interferon treatment clear the hepatitis B virus more completely. It's designed for patients whose virus levels dropped significantly during their first treatment but haven't gone away.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
10,000 people
Ages
18 years to 65 years
Study type
Observational

Who can take part

  • You are 18–65 years old
  • You have had hepatitis B for at least 6 months, confirmed by blood tests
  • You previously received interferon treatment and stopped at least 3 months ago, with your viral load dropping by at least 50% during that treatment
  • Your current hepatitis B viral level is low (≤500 IU/mL) and hasn't rebounded more than 50% since your first treatment
  • You are willing to use reliable contraception during the study (women must have a negative pregnancy test before starting)
  • You do not have other liver diseases, serious mental health conditions, or uncontrolled medical conditions like diabetes, thyroid disease, or high blood pressure

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06323681Recruiting
Lower-dose interferon for chronic hepatitis B patients who've tried it before

This study tests a lower dose of pegylated interferon for people with chronic hepatitis B whose virus levels dropped significantly during a previous interferon treatment. It aims to see if a second round can further reduce or clear the virus.

Shanghai, Shanghai Municipality
NCT06368882Recruiting· Phase 4
Peg-interferon for hepatitis B with fatty liver

This trial tests a medicine called peg-interferon for people who have both chronic hepatitis B and fatty liver. It aims to see if the treatment is safe and effective in helping your body fight the hepatitis B virus.

Ningbo
NCT04896255Recruiting
Long-term follow-up of hepatitis B treatments

This study looks at long-term outcomes in people with chronic hepatitis B who take antiviral medicines or receive interferon. It may help doctors understand which treatments work best over time and who is most likely to benefit.

Shanghai
NCT06900166Not yet recruiting· Phase 4
Peginterferon to reduce relapse after stopping hepatitis B treatment

This trial tests whether adding pegylated interferon alfa-2b can help people with hepatitis B stay virus-free after they stop their current oral antiviral medication. It is for patients who have had undetectable virus for over 3 years and have low levels of hepatitis B surface antigen.

Shanghai, Shanghai Municipality
NCT06920329Not yet recruiting
Peginterferon therapy for hepatitis B with clinical cure

This study tests whether additional peginterferon treatment can further reduce the virus in the liver for people with chronic hepatitis B who have already reached a clinical cure. You would need to have two liver biopsies to check the virus levels.

Xiamen, Fujian
NCT07071636Not yet recruiting· Phase 4
Peginterferon plus nucleoside therapy for chronic hepatitis B

This study tests whether adding a pegylated interferon (a medicine that boosts your immune system) to your current hepatitis B treatment can help lower your hepatitis B virus levels even more. It is for people with chronic hepatitis B who have not had interferon recently and do not have fatty liver disease.

Hear when a new Chronic Hepatitis B trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.